SEC Comment Letter 0000000000-25-001350 to Kezar Life Sciences, Inc. (KZR) (CIK 0001645666) (KZR)
Kezar Life Sciences, Inc. (KZR) (CIK 0001645666)
Date: Feb. 7, 2025 · CIK: 0001645666 · Accession: 0000000000-25-001350
AI Filing Summary & Sentiment
File numbers found in text: 333-284712
Letter
February 7, 2025 Christopher Kirk Chief Executive Officer Kezar Life Sciences, Inc. 4000 Shoreline Court, Suite 300 South San Francisco, CA 94080 Re:Kezar Life Sciences, Inc. Registration Statement on Form S-3 Filed February 5, 2025 File No. 333-284712 Dear Christopher Kirk: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jaime L. Chase, Esq.
Show Raw Text
February 7, 2025
Christopher Kirk
Chief Executive Officer
Kezar Life Sciences, Inc.
4000 Shoreline Court, Suite 300
South San Francisco, CA 94080
Re:Kezar Life Sciences, Inc.
Registration Statement on Form S-3
Filed February 5, 2025
File No. 333-284712
Dear Christopher Kirk:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jaime L. Chase, Esq.